Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) spent $1.66 billion on lobbying in the US in the first half, 7% less than in the first half of 2009. The company spent $840,000 on lobbying in the second quarter of 2010, the same as in the corresponding quarter of 2009, according to the lobbying report filed by Teva Pharmaceuticals USA Inc. Spending rose 2.4% over the first quarter.
Teva lobbies Congress, the US administration, the Office of Patents and Trademarks, US Trade Representative, and other federal agencies.
Germany's Ratiopharm GmbH, which Teva acquired in March, today reported that first half revenue rose 1%, while its earnings before interest, taxes, depreciation and amortization (EBITDA) rose 20% to €158 million.
Teva's share price opened at $54.33 on Nasdaq today. The share price rose 0.2% on the TASE today to NIS 207.50.
Published by Globes [online], Israel business news - www.globes-online.com - on July 19, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010